Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance.
We previously demonstrated that infusion of an intestinal peptide called xenin-25 (Xen) amplifies the effects of glucose-dependent insulinotropic polypeptide (GIP) on insulin secretion rates (ISRs) and plasma glucagon levels in humans. However, these effects of Xen, but not GIP, were blunted in huma...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5821323?pdf=render |
_version_ | 1811199889612210176 |
---|---|
author | Songyan Wang Lauren Z Oestricker Michael J Wallendorf Karin Sterl Judit Dunai C Rachel Kilpatrick Bruce W Patterson Dominic N Reeds Burton M Wice |
author_facet | Songyan Wang Lauren Z Oestricker Michael J Wallendorf Karin Sterl Judit Dunai C Rachel Kilpatrick Bruce W Patterson Dominic N Reeds Burton M Wice |
author_sort | Songyan Wang |
collection | DOAJ |
description | We previously demonstrated that infusion of an intestinal peptide called xenin-25 (Xen) amplifies the effects of glucose-dependent insulinotropic polypeptide (GIP) on insulin secretion rates (ISRs) and plasma glucagon levels in humans. However, these effects of Xen, but not GIP, were blunted in humans with type 2 diabetes. Thus, Xen rather than GIP signaling to islets fails early during development of type 2 diabetes. The current crossover study determines if cholinergic signaling relays the effects of Xen on insulin and glucagon release in humans as in mice. Fasted subjects with impaired glucose tolerance were studied. On eight separate occasions, each person underwent a single graded glucose infusion- two each with infusion of albumin, Xen, GIP, and GIP plus Xen. Each infusate was administered ± atropine. Heart rate and plasma glucose, insulin, C-peptide, glucagon, and pancreatic polypeptide (PP) levels were measured. ISRs were calculated from C-peptide levels. All peptides profoundly increased PP responses. From 0 to 40 min, peptide(s) infusions had little effect on plasma glucose concentrations. However, GIP, but not Xen, rapidly and transiently increased ISRs and glucagon levels. Both responses were further amplified when Xen was co-administered with GIP. From 40 to 240 min, glucose levels and ISRs continually increased while glucagon concentrations declined, regardless of infusate. Atropine increased resting heart rate and blocked all PP responses but did not affect ISRs or plasma glucagon levels during any of the peptide infusions. Thus, cholinergic signaling mediates the effects of Xen on insulin and glucagon release in mice but not humans. |
first_indexed | 2024-04-12T01:55:19Z |
format | Article |
id | doaj.art-dbb5a054db5b452f96f572e3a993bda6 |
institution | Directory Open Access Journal |
issn | 1932-6203 |
language | English |
last_indexed | 2024-04-12T01:55:19Z |
publishDate | 2018-01-01 |
publisher | Public Library of Science (PLoS) |
record_format | Article |
series | PLoS ONE |
spelling | doaj.art-dbb5a054db5b452f96f572e3a993bda62022-12-22T03:52:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01132e019244110.1371/journal.pone.0192441Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance.Songyan WangLauren Z OestrickerMichael J WallendorfKarin SterlJudit DunaiC Rachel KilpatrickBruce W PattersonDominic N ReedsBurton M WiceWe previously demonstrated that infusion of an intestinal peptide called xenin-25 (Xen) amplifies the effects of glucose-dependent insulinotropic polypeptide (GIP) on insulin secretion rates (ISRs) and plasma glucagon levels in humans. However, these effects of Xen, but not GIP, were blunted in humans with type 2 diabetes. Thus, Xen rather than GIP signaling to islets fails early during development of type 2 diabetes. The current crossover study determines if cholinergic signaling relays the effects of Xen on insulin and glucagon release in humans as in mice. Fasted subjects with impaired glucose tolerance were studied. On eight separate occasions, each person underwent a single graded glucose infusion- two each with infusion of albumin, Xen, GIP, and GIP plus Xen. Each infusate was administered ± atropine. Heart rate and plasma glucose, insulin, C-peptide, glucagon, and pancreatic polypeptide (PP) levels were measured. ISRs were calculated from C-peptide levels. All peptides profoundly increased PP responses. From 0 to 40 min, peptide(s) infusions had little effect on plasma glucose concentrations. However, GIP, but not Xen, rapidly and transiently increased ISRs and glucagon levels. Both responses were further amplified when Xen was co-administered with GIP. From 40 to 240 min, glucose levels and ISRs continually increased while glucagon concentrations declined, regardless of infusate. Atropine increased resting heart rate and blocked all PP responses but did not affect ISRs or plasma glucagon levels during any of the peptide infusions. Thus, cholinergic signaling mediates the effects of Xen on insulin and glucagon release in mice but not humans.http://europepmc.org/articles/PMC5821323?pdf=render |
spellingShingle | Songyan Wang Lauren Z Oestricker Michael J Wallendorf Karin Sterl Judit Dunai C Rachel Kilpatrick Bruce W Patterson Dominic N Reeds Burton M Wice Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance. PLoS ONE |
title | Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance. |
title_full | Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance. |
title_fullStr | Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance. |
title_full_unstemmed | Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance. |
title_short | Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance. |
title_sort | cholinergic signaling mediates the effects of xenin 25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance |
url | http://europepmc.org/articles/PMC5821323?pdf=render |
work_keys_str_mv | AT songyanwang cholinergicsignalingmediatestheeffectsofxenin25onsecretionofpancreaticpolypeptidebutnotinsulinorglucagoninhumanswithimpairedglucosetolerance AT laurenzoestricker cholinergicsignalingmediatestheeffectsofxenin25onsecretionofpancreaticpolypeptidebutnotinsulinorglucagoninhumanswithimpairedglucosetolerance AT michaeljwallendorf cholinergicsignalingmediatestheeffectsofxenin25onsecretionofpancreaticpolypeptidebutnotinsulinorglucagoninhumanswithimpairedglucosetolerance AT karinsterl cholinergicsignalingmediatestheeffectsofxenin25onsecretionofpancreaticpolypeptidebutnotinsulinorglucagoninhumanswithimpairedglucosetolerance AT juditdunai cholinergicsignalingmediatestheeffectsofxenin25onsecretionofpancreaticpolypeptidebutnotinsulinorglucagoninhumanswithimpairedglucosetolerance AT crachelkilpatrick cholinergicsignalingmediatestheeffectsofxenin25onsecretionofpancreaticpolypeptidebutnotinsulinorglucagoninhumanswithimpairedglucosetolerance AT brucewpatterson cholinergicsignalingmediatestheeffectsofxenin25onsecretionofpancreaticpolypeptidebutnotinsulinorglucagoninhumanswithimpairedglucosetolerance AT dominicnreeds cholinergicsignalingmediatestheeffectsofxenin25onsecretionofpancreaticpolypeptidebutnotinsulinorglucagoninhumanswithimpairedglucosetolerance AT burtonmwice cholinergicsignalingmediatestheeffectsofxenin25onsecretionofpancreaticpolypeptidebutnotinsulinorglucagoninhumanswithimpairedglucosetolerance |